Home Cart 0 Sign in  

[ CAS No. 143557-91-9 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 143557-91-9
Chemical Structure| 143557-91-9
Structure of 143557-91-9 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 143557-91-9 ]

Related Doc. of [ 143557-91-9 ]

Alternatived Products of [ 143557-91-9 ]

Product Details of [ 143557-91-9 ]

CAS No. :143557-91-9 MDL No. :MFCD22409620
Formula : C12H21NO3 Boiling Point : -
Linear Structure Formula :- InChI Key :-
M.W : 227.30 Pubchem ID :-
Synonyms :

Calculated chemistry of [ 143557-91-9 ]

Physicochemical Properties

Num. heavy atoms : 16
Num. arom. heavy atoms : 0
Fraction Csp3 : 0.92
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 1.0
Molar Refractivity : 65.25
TPSA : 49.77 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.55 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.62
Log Po/w (XLOGP3) : 1.6
Log Po/w (WLOGP) : 1.53
Log Po/w (MLOGP) : 1.44
Log Po/w (SILICOS-IT) : 0.69
Consensus Log Po/w : 1.58

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.06
Solubility : 1.98 mg/ml ; 0.00872 mol/l
Class : Soluble
Log S (Ali) : -2.26
Solubility : 1.26 mg/ml ; 0.00554 mol/l
Class : Soluble
Log S (SILICOS-IT) : -0.8
Solubility : 36.4 mg/ml ; 0.16 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.94

Safety of [ 143557-91-9 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 143557-91-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 143557-91-9 ]
  • Downstream synthetic route of [ 143557-91-9 ]

[ 143557-91-9 ] Synthesis Path-Upstream   1~22

  • 1
  • [ 143557-91-9 ]
  • [ 14383-51-8 ]
Reference: [1] Patent: US2007/66584, 2007, A1, . Location in patent: Page/Page column 30
  • 2
  • [ 24424-99-5 ]
  • [ 538-09-0 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
100% With triethylamine In dichloromethane at 0 - 20℃; for 12 h; enαto-8-Azabicyclo[3.2.1]octan-3-ol (3.6g, 28.3mmol) was dissolved in DCM (50ml) and cooled to O0C. Triethylamine (7.8ml, 56.7mmol) was added followed by addition of butyl dicarbonate (7.4g, 33.9mmol). The reaction mixture was warmed to ambient temperature and stirred for 12h. The reaction mixture was diluted with water. The organic layer was separated and washed with saturated citric acid (aq), water and brine. The organic layer was dried over MgSO4 and concentrated in vacuo to afford 3-enαto-hydroxy- 8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester as a white solid (6.45g, 28.4mmol, 100percent). M.S. (ESI) (m/z): 228 [M+H]+
97% at 20℃; Step 1:
3-endo-3-Hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
To a stirred suspension of nortropine (1.272 g, 1 eq.) in tetrahydrofuran (25 mL) was added di-tert-butyl-dicarbonate (2.292 g, 1.05 eq.).
The mixture was stirred overnight at room temperature.
The solvent was evaporated under reduced pressure and the residue purified by column chromatography on silica gel eluding with a 1:0 to 4:1 gradient of dichloromethane/ethyl acetate, to yield 2.207 g (97percent) of the title compound as colourless solid. MS (m/e) 227.2 (M+)
97% With triethylamine In dichloromethane at 20℃; for 16 h; To a solution of (3-exo)-8-azabicyclo[3.2.1]octan-3-ol (0.95 g, 7.5 mmol) and triethylamine (1.7 mL, 12.2 mmol) in DCM (10 mL) was added di-tert-butyl dicarbonate (3.27 g, 15.0 mmol) portionwise and the resulting reaction mixture stirred at RT for 16 h. The reaction mixture was diluted with water then the organic layer was separated and washed with saturated citric acid (aq), water andbrine. The organic layer was dried over MgSO4, filtered and concentrated under reduced pressure to afford 1 .65 g (97percent yield) of the title compound as an off whitesolid.1H NMR (250 MHz, Chloroform-d): 6 [ppm] 4.41 - 3.95 (m, 3H), 2.00 - 1 .53 (m, 9H),1.45 (5, 9H).
93% With sodium hydroxide In tetrahydrofuran at 20℃; Compound 1 (10 g, 0.079 mol) was taken up in tetrahydrofuran (200 mL) followed by the addition of BOC-anhydride (17.2 g, 0.079 mol) in one portion. The solution was stirred at room temperature for overnight and then concentrated in vacuo to a brown solid. The crude product was taken up in 95percent dichloromethane/5percent) methanol and added to a pad of silica gel (elution with 95percent dichloromethane/5percent methanol). Fractions containing compound 2 were combined and concentrated to a white solid. Yield: 16.6 g (93percent); MS [M+H]+ 171.8 (M-56), 127.8 (M-100); 1HNMR (DMSO-d6) 54.59 (s, 1H), 3.98-3.91 (m, 3H), 2.11 (bs, 2H), 1.85 (m, 4H), 1.64 (m, 2H), 1.47 (s, 9H) ppm.
80% at 20℃; for 1 h; 4j: (lS,3R,5R)-3-Hvdroxy-8-aza-bicvclo[3.2.1]octane-8-carboxylic acid tert-butyl ester O Nortropine (78 mmol) was dissolved in dry THF (250 mL), and di-tert-butyl-dicarbonate (82 mmol) was added. Stirred at ambient temperature for Ih. The solvent was removed by evaporation and the resisue recrystallized from ethyl acetate/heptane. The product was collected and dried in vacuo. Yield = 80percent 1H NMR (D6-DMSO): 1.38 (s, 9H); 1.61 (m, 2H); 1.70-1.93 (4H); 2.12 (m, 2H); 3.91 (br; IH); 3.99 (br, 2H); 4.58 (s, IH).
9 g With triethylamine In ethanol at 25℃; To a solution of (1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-ol (5.0 g) in ethanol (100 mL) was added TEA (11.0 mL) and Boc2O (10.0 mL). The resulting mixture was stirred at 25°C overnight, and then concentrated under reduced pressure to afford (1 R,3r,5S)-tert-butyl 3- hydroxy-8-azabicyclo[3.2.1 ]octane-8-carboxylate (9.0 g).

Reference: [1] Patent: WO2007/63071, 2007, A1, . Location in patent: Page/Page column 15
[2] Patent: US2007/123525, 2007, A1, . Location in patent: Page/Page column 20
[3] Patent: WO2016/91776, 2016, A1, . Location in patent: Page/Page column 210; 211
[4] Patent: WO2014/152144, 2014, A1, . Location in patent: Paragraph 0190
[5] Patent: WO2009/106534, 2009, A1, . Location in patent: Page/Page column 73
[6] Organic and Biomolecular Chemistry, 2004, vol. 2, # 19, p. 2861 - 2869
[7] Patent: WO2006/18279, 2006, A2, . Location in patent: Page/Page column 63-64
[8] Patent: WO2007/93366, 2007, A1, . Location in patent: Page/Page column 104
[9] Patent: WO2013/16197, 2013, A1, . Location in patent: Page/Page column 90
[10] Patent: WO2015/181186, 2015, A1, . Location in patent: Page/Page column 156
[11] Patent: US9522906, 2016, B2, . Location in patent: Page/Page column 104
[12] Journal of the American Chemical Society, 2018, vol. 140, # 4, p. 1207 - 1210
  • 3
  • [ 936701-56-3 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
80% at 20℃; for 72 h; A mixture of endo-3-benzoyloxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (55.0 g, 166 mmol), potassium hydroxide (11.2 g 199 mmol) and ethanol (99percent, 400 ml) was stirred for 3 days at room temperature. Potassium benzoate was separated by filtration and the filtrate was evaporated. Diethylether (200 ml) was added and remaining potassium benzoate was separated by filtration and the filtrate was evaporated. The product was triturated with petroleum. Yield 30.0 g (80percent). Mp 139.5-140.8° C.
80% at 20℃; for 72 h; 30 enc/o-3-Hvdroxy-8-aza-bicvclo[3.2.11octane-8-carboxylic acid fe/f-butyl esterA mixture of enc/o-3-benzoyloxy-8-aza-bicyclo[3.2.1 ]octane-8-carboxylic acid terf-butyl ester (55.0 g, 166 mmol), potassium hydroxide (1 1 .2 g 199 mmol) and ethanol (99percent, 400 ml) was stirred for 3 days at room temperature. Potassium benzoate was separated by filtration and the filtrate was evaporated. Diethylether (200 ml) was added and remaining potassium benzoate was separated by filtration and the filtrate was evaporated. The product was triturated with petroleum. Yield 30.0 g (80percent). Mp 139.5-140.8°C.
80% at 20℃; for 72 h; encto-3-Hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid terf-butyl ester; A mixture of enc/o-3-benzoyloxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (55.0 g, 166 mmol), potassium hydroxide (1 1.2 g 199 mmol) and ethanol (99percent, 15 400 ml) was stirred for 3 days at room temperature. Potassium benzoate was separated by filtration and the filtrate was evaporated. Diethylether (200 ml) was added and remaining potassium benzoate was separated by filtration and the filtrate was evaporated. The product was triturated with petroleum. Yield 30.0 g (80percent). Mp 139.5- 140.80C.
80% With potassium hydroxide In ethanol at 20℃; for 72 h; A mixture of enc/o-3-benzoyloxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid te/t-butyl ester (55.0 g, 166 mmol), potassium hydroxide (11.2 g 199 mmol) and ethanol (99percent, 400 ml) was stirred for 3 days at room temperature. Potassium benzoate was separated by filtration and the filtrate was evaporated. Diethylether (200 ml) was added and remaining potassium benzoate was separated by filtration and the filtrate was evaporated. The product was triturated with petroleum. Yield 30.0 g (80percent). Mp 139.5-140.8°C.

Reference: [1] Patent: US2012/4257, 2012, A1, . Location in patent: Page/Page column 7
[2] Patent: WO2012/881, 2012, A1, . Location in patent: Page/Page column 15
[3] Patent: WO2008/74797, 2008, A1, . Location in patent: Page/Page column 15
[4] Patent: WO2008/74798, 2008, A1, . Location in patent: Page/Page column 15
[5] Patent: WO2010/130620, 2010, A1, . Location in patent: Page/Page column 14
[6] Patent: WO2011/92061, 2011, A1, . Location in patent: Page/Page column 13-14
  • 4
  • [ 652148-00-0 ]
  • [ 34619-03-9 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
37% With hydrogen In ethanol for 72 h; To a solution of 8- (4-fluoro-benzyl)-8-aza-bicyclo [3.2. 1] octanol (5.02 grams, 21.4 [MMOL)] in ethanol (150 ml) in a Par bottle was added carbonic acid di- ter-butyl ester (5.5 grams, 25.2 [MMOL)] and palladium hydroxide on carbon (0.3 grams, 20percent on carbon). The reaction mixture was subject to 50 psi hydrogen gas for 3 days. The reaction mixture was then filtered through a 0. [54, UM FILTER.] Concentration of the filtrate in vacuo followed by chromatography on silica gel gave the title compounds, (cis) (1.8 grams, 37percent yield) and (trans) (2.3 grams, 47percent yield)
Reference: [1] Patent: WO2004/9588, 2004, A1, . Location in patent: Page 49
  • 5
  • [ 185099-67-6 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
25% at 20℃; Inert atmosphere Stage (i): (1 R,3R,5S)-tert-Butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate and (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate Boc-nortropinone (2,5 g, 11 ,097 mmol) was dissolved in methanol (20 ml) and cooled with an ice bath. Sodium boron hydride (1.26 g, 33.291 mmol) was added slowly under protective gas. After stirring for 4 h at RT the mixture was hydrolysed with saturated sodium hydrogen carbonate solution (30 ml), the methanol was removed under vacuum and the aqueous phase extracted with ethyl acetate (3 x 50 ml). The combined organic phases were dried over magnesium sulfate and concentrated to small volume under vacuum. The crude product was purified by column chromatography (silica gel) with ethyl acetate/methanol/dichloromethane/ ammonia (25percent eq.) (400:40:40:1). The isomers were separated in this process and they were assigned by NMR analysis. Yield: endo 53percent [reacted further in stage (N)], exo 25percent
25% at 20℃; Cooling; Inert atmosphere Stage (i): (1R,3R,5S)-tert-Butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate and (1R,3s,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylateBoc-nortropinone (2.5 g, 11.097 mmol) was dissolved in methanol (20 ml) and the solution was cooled with an ice bath. Sodium borohydride (1.26 g, 33.291 mmol) was added slowly under an inert gas. After stirring at room temperature for 4 h, hydrolysis was carried out with saturated sodium bicarbonate solution (30 ml), methanol was removed in vacuo and the aqueous phase was extracted with ethyl acetate (3.x.50 ml). The combined organic phases were dried over magnesium sulfate and concentrated in vacuo. The crude product was purified by column chromatography (silica gel) with ethyl acetate/methanol/methylene chloride/ammonia (25 aq) (400:40:40:1). The isomers were separated by this procedure; this was assigned by NMR analysis. Yield: endo 50percent [reacted further in stage (ii)], exo 25percent
47.3% at 0 - 20℃; for 16 h; Step 2. Preparation of (1R,3R,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate and (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate To a stirred solution of (1R,5S)-tert-butyl 3-oxo-8-azabicyclo[3.2.1]octane-8-carboxy late (3.14 g, 13.9 mmol) in MeOH (25 mL) was added sodium borohydride (0.791 g, 20.9 mmol) portion wise at 0° C. The ice bath was removed and the stirring continued for 16 hours at room temperature. The mixture was diluted with DCM and washed with water. The organic phase was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography on SiO2 (Hex:EtOAc=3:1) to give the (1R,3R,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate, endo product (1.50 g, 47.3percent) and (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate, exo product (1.18 g, 37.2percent) as a white solid each.Endo isomer; (1R,3R,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate1H-NMR (400 MHz, CDCl3) δ 1.46 (9H, s), 1.69 (2H, d), 1.94-2.16 (6H, m), 4.14-4.22 (3H, m).Exo isomer; (1R,3S,5S)-tert-butyl 3-hydroxy-8-azabicyclo[3.2.1]octane-8-carboxylate1H-NMR (400 MHz, CDCl3) δ 1.47 (9H, s). 1.56-1.62 (4H, m), 1.95 (4H, m), 4.11-4.28 (3H, m).
19.7% at 20℃; for 24 h; Inert atmosphere Synthesis of bicyclic amine intermediates Bicyclic amine 1 : 3-Hydroxy-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl esterTo a solution of 3-oxo-8-aza-bicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (1.03 g, 4.57 mmol) in EtOH (20 mL) was added NaBH4 dropwise. The mixture was stirred for 4.5 hours at room temperature under nitrogen, followed by a second addition of NaBH4 (0.36 g, 9.60 mmol). The reaction was stirred at room temperature for 17.5 hours and a last addition of NaBH4 (0.36 g, 9.60 mmol) was performed. The solution was stirred at room temperature for 2 hours, then a saturated solution of ammonium chloride was added and the aqueous phase was extracted with EtOAc. The combined organic fractions were dried over Na2S04, filtered and concentrated. The crude was purified by flash chromatography on silica gel using cyclohexane/EtOAc as eluent to yield, after evaporation, to the axial and equatorial isomers (186 mg, 17.9percent) and (205 mg, 19.7percent) as white solids. 1 H NMR (600 MHz, CDCI3): 4.57 (d, 1 H), 4.02 (m, 2H), 3.89 (d, 1 Hax), 1.89 - 1.71 (m, 5H), 1.65 - 1 .54 (m, 1 H), 1.47 - 1.28 (m, 1 1 H) and 4.60 (d, 1 H) 3.99 (m, 2H), 3.91 (m, 1 Heq), 2.18 - 2.03 (m, 2H), 1 .92 - 1 .72 (m, 4H), 1.67 - 1.56 (m, 2H), 1 .39 (s, 9H)

Reference: [1] Patent: WO2010/99938, 2010, A1, . Location in patent: Page/Page column 106
[2] Patent: US2010/152158, 2010, A1, . Location in patent: Page/Page column 30
[3] Patent: US2012/53180, 2012, A1, . Location in patent: Page/Page column 33
[4] Patent: WO2013/61305, 2013, A1, . Location in patent: Page/Page column 44
[5] Patent: EP937069, 2006, B1, . Location in patent: Page/Page column 65
[6] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 11, p. 3290 - 3296
[7] Patent: US2012/225876, 2012, A1, . Location in patent: Page/Page column 32
  • 6
  • [ 185099-67-6 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
46% at 0 - 20℃; Example 5 Preparation of Intermediate Compounds 5 A and 5B; iV-BOC-nortropinone (1.38 g, 6.13mmol) was dissolved in methanol (21 niL) and the resulting solution was cooled to 0 0C. Sodium borohydride (0.59 g, 15.68 mmol) was slowly added to the cooled solution and the resulting reaction was allowed to stir for 1 hour at room temperature. The reaction mixture was quenched with saturated ammonium chloride solution and extracted 2 times with dichloromethane. The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuo to provide a residue which was purified using flash column chromatography on silica gel (hexane/ ethyl acetate (60/40)) to provide endo-product 5A (0.63 g, 46percent) and exo-product alcohol 5B (0.64 g, 46percent).
Reference: [1] Journal of Medicinal Chemistry, 2009, vol. 52, # 14, p. 4111 - 4114
[2] Patent: WO2010/9195, 2010, A1, . Location in patent: Page/Page column 82
[3] Patent: WO2008/101914, 2008, A2, . Location in patent: Page/Page column 68
  • 7
  • [ 185099-67-6 ]
  • [ 143557-91-9 ]
YieldReaction ConditionsOperation in experiment
45% at 20℃; Cooling with ice A stirred solution of Boc-nortropinone (930 mg, 4.1 mmol) in MeOH (40 mL) was cooled in an ice bath and a NaBH4 caplet (1 g, 26.7 mmol) was added. The ice bath was allowed to melt and stirring was continued overnight at rt. The mixture was concentrated to leave a white solid which was partitioned between EtOAc (100 mL), brine (10 mL) and water (10 mL). The organic layer was separated, dried over Na2SO4 and concentrated to leave an oil (966 mg). Chromatography on a 40-g silica gel cartridge eluted with a 0-100percent EtOAc in hexanes gradient afforded two isomeric alcohols. The less polar alcohol, (1R,3r,5S)-tert-butyl 3-hydroxy-8- azabicyclo[3.2.1]octane-8-carboxylate, was isolated (462 mg, 45percent).
Reference: [1] Patent: WO2009/131669, 2009, A2, . Location in patent: Page/Page column 107-108
[2] Patent: US2007/179158, 2007, A1, . Location in patent: Page/Page column 22
  • 8
  • [ 28957-72-4 ]
  • [ 24424-99-5 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US5968929, 1999, A,
  • 9
  • [ 7432-11-3 ]
  • [ 24424-99-5 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US2010/173889, 2010, A1, . Location in patent: Page/Page column 63
  • 10
  • [ 185099-67-6 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2010/75273, 2010, A1, . Location in patent: Page/Page column 87-88
[2] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 11, p. 3290 - 3296
  • 11
  • [ 936701-56-3 ]
  • [ 582-25-2 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2007/93604, 2007, A1, . Location in patent: Page/Page column 15
  • 12
  • [ 120-29-6 ]
  • [ 143557-91-9 ]
Reference: [1] Organic and Biomolecular Chemistry, 2004, vol. 2, # 19, p. 2861 - 2869
[2] Patent: WO2011/92061, 2011, A1,
[3] Patent: US2012/4257, 2012, A1,
[4] Patent: WO2012/881, 2012, A1,
[5] Patent: WO2008/74797, 2008, A1,
[6] Patent: WO2008/74798, 2008, A1,
  • 13
  • [ 24424-99-5 ]
  • [ 120-29-6 ]
  • [ 143557-91-9 ]
Reference: [1] Journal of Organic Chemistry, 2002, vol. 67, # 25, p. 8970 - 8974
  • 14
  • [ 34619-03-9 ]
  • [ 538-09-0 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2007/93365, 2007, A2, . Location in patent: Page/Page column 93; 100-101
  • 15
  • [ 18470-33-2 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2011/92061, 2011, A1,
[2] Patent: US2012/4257, 2012, A1,
[3] Patent: WO2012/881, 2012, A1,
[4] Patent: WO2008/74797, 2008, A1,
[5] Patent: WO2008/74798, 2008, A1,
[6] Patent: WO2010/130620, 2010, A1,
  • 16
  • [ 19145-60-9 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2011/92061, 2011, A1,
[2] Patent: US2012/4257, 2012, A1,
[3] Patent: WO2012/881, 2012, A1,
[4] Patent: WO2008/74797, 2008, A1,
[5] Patent: WO2008/74798, 2008, A1,
[6] Patent: WO2010/130620, 2010, A1,
  • 17
  • [ 24424-99-5 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US2012/53180, 2012, A1,
  • 18
  • [ 28957-72-4 ]
  • [ 194222-05-4 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US2012/53180, 2012, A1,
  • 19
  • [ 813420-07-4 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2011/92061, 2011, A1,
  • 20
  • [ 24424-99-5 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: US2012/225876, 2012, A1,
  • 21
  • [ 7432-10-2 ]
  • [ 143557-91-9 ]
Reference: [1] Patent: WO2010/130620, 2010, A1,
  • 22
  • [ 143557-91-9 ]
  • [ 744183-20-8 ]
Reference: [1] Patent: US2012/225876, 2012, A1,
[2] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 14, p. 4080 - 4087
[3] Patent: WO2009/106534, 2009, A1,
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 143557-91-9 ]

Alcohols

Chemical Structure| 250249-85-5

[ 250249-85-5 ]

(R)-1-Boc-piperidine-2-ethanol

Similarity: 0.96

Chemical Structure| 1502162-73-3

[ 1502162-73-3 ]

tert-Butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 207405-60-5

[ 207405-60-5 ]

tert-Butyl 5-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate

Similarity: 0.93

Chemical Structure| 348165-62-8

[ 348165-62-8 ]

(2R,4S)-tert-Butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 114676-61-8

[ 114676-61-8 ]

(2S,4R)-tert-Butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate

Similarity: 0.92

Amides

Chemical Structure| 250249-85-5

[ 250249-85-5 ]

(R)-1-Boc-piperidine-2-ethanol

Similarity: 0.96

Chemical Structure| 1502162-73-3

[ 1502162-73-3 ]

tert-Butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 207405-60-5

[ 207405-60-5 ]

tert-Butyl 5-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate

Similarity: 0.93

Chemical Structure| 348165-62-8

[ 348165-62-8 ]

(2R,4S)-tert-Butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 114676-61-8

[ 114676-61-8 ]

(2S,4R)-tert-Butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate

Similarity: 0.92

Related Parent Nucleus of
[ 143557-91-9 ]

Aliphatic Heterocycles

Chemical Structure| 250249-85-5

[ 250249-85-5 ]

(R)-1-Boc-piperidine-2-ethanol

Similarity: 0.96

Chemical Structure| 1502162-73-3

[ 1502162-73-3 ]

tert-Butyl 4-hydroxy-2,2-dimethylpiperidine-1-carboxylate

Similarity: 0.94

Chemical Structure| 207405-60-5

[ 207405-60-5 ]

tert-Butyl 5-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate

Similarity: 0.93

Chemical Structure| 348165-62-8

[ 348165-62-8 ]

(2R,4S)-tert-Butyl 4-hydroxy-2-methylpyrrolidine-1-carboxylate

Similarity: 0.92

Chemical Structure| 744183-20-8

[ 744183-20-8 ]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.92

Other Aliphatic Heterocycles

Chemical Structure| 207405-60-5

[ 207405-60-5 ]

tert-Butyl 5-hydroxy-2-aza-bicyclo[2.2.1]heptane-2-carboxylate

Similarity: 0.93

Chemical Structure| 207405-68-3

[ 207405-68-3 ]

tert-Butyl endo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.92

Chemical Structure| 744183-20-8

[ 744183-20-8 ]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.92

Chemical Structure| 478832-21-2

[ 478832-21-2 ]

tert-Butyl 4-hydroxyazepane-1-carboxylate

Similarity: 0.92

Chemical Structure| 1147422-00-1

[ 1147422-00-1 ]

tert-Butyl octahydro-1H-pyrrolo[3,2-c]pyridine-1-carboxylate

Similarity: 0.89